LATEST UPDATES » Vol 23, No 06, June 2019 – Clinical trials — What's in a name?       » Study reveals mechanism behind ginger's warming effect on body       » China proposes major changes to pharmaceutical regulations       » Six plants native to Southeast Asia are promising cancer warriors       » Cancer cells are addicted to methionine       » World's first molecular swing      
Medopad and Tencent develop advanced AI for Parkinson’s disease
New motor function test allows patients to be assessed outside of the clinical setting in just 3 minutes – 10 times faster than the standard clinician appointment

A new project will use AI technology to assess the motor function of people with Parkinson’s in a real-world setting to greatly reduce evaluation time, improve efficiency, and reduce costs.

Working together on the joint research and development initiative are British HealthTech company Medopad, Chinese tech giant Tencent, and Ray Chaudhuri, Professor of Movement Disorders and Director of the Parkinson's Centre of Excellence at King's College Hospital in London.

Dr. Wei Fan, head of Tencent Medical AI Lab cited Parkinson’s disease as the third most common condition in China after diabetes and cancer.

Currently, Parkinson's disease motor function assessment takes more than 30 minutes in a clinical setting. The doctor asks the patient to perform a series of actions and scores the patient’s motor function against a standard scale based on multiple factors such as distance, amplitude, and action frequency. The scoring is ultimately assigned based on the assessor’s observations, therefore lacks standardised quantitative indicators, resulting in a low capacity to detect small variations and leaving the assessment prone to generating inconsistent results.

To standardise this test and enable patients to complete it remotely, Medopad and Tencent Medical AI Lab are using motion video analysis technology that leverages deep learning and image recognition to quantify motor functions. The AI model was developed by setting hundreds of identifiable key nodes on the human body and using detectors to track the frequency, distance, and changes in angles and speeds of movements. With the aid of this AI technology, Tencent’s Parkinson's disease motor function intelligent assessment system can quantify and improve the accuracy of motion evaluation.

Medopad’s smartphone technology allows patients to perform a motor function assessment outside of the clinical setting, share the results in real-time, and enable doctors to more efficiently and effectively evaluate a patient’s progress. This technology will revolutionise the way doctors carry out their medical consultation: patients will be able to be assessed outside of the clinical setting in just three minutes – 10 times faster than the standard clinician appointment.

The technology has been validated in China, the UK is expected to be next.

Source: Medopad

Click here for the complete issue.

news Discover key nutraceutical trends in Asia Pacific
news Which country has the worst sleepers
news Asia is the fastest growing region for nutraceuticals
news 2018 Nobel Prize in Physiology or Medicine winners
Asia Pacific Biotech News

APBN Editorial Calendar 2019
Taiwan Medical tourism
Marijuana as medicine — Legal marijuana will open up scientific research
Driven by curiosity
Career developments for researchers
What's cracking — Antibodies in ostrich eggs
Clinical trials — What's in a name?
Editorial calendar is subjected to changes.
About Us
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
Copyright© 2019 World Scientific Publishing Co Pte Ltd  •  Privacy Policy